Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report.

Joan Manel Gasent Blesa¹, Vicente Alberola Candel

¹Department of Medical Oncology, Hospital de Dènia, Marina Salud, Dénia, Spain.

Case Reports in Oncology

|August 27, 2010

Summary

Metastatic prostate cancer requires new treatments. Fulvestrant acetate showed promise by controlling prostate-specific antigen (PSA) levels in a patient with advanced, hormone-resistant prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL study.

Journal of opioid management·2014

Same author

Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab.

Case reports in oncology·2013

Same author

PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report.

Case reports in oncology·2012

Same author

Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer.

Journal of gastrointestinal cancer·2012

Same author

Old and new insights in the treatment of thyroid carcinoma.

Journal of thyroid research·2010

Same author

Final Report of the First Refractory Germ Cell Tumor Treated with Sunitinib Malate.

Case reports in oncology·2010

Area of Science:

Oncology
Endocrinology

Background:

Metastatic prostate cancer is typically incurable, progressing to androgen-independent growth after hormone therapy.
Chemotherapy is often challenging in elderly or fragile patients, necessitating novel therapeutic strategies.
Preclinical studies suggest estrogen receptor (ER) signaling plays a role in prostate cancer progression.

Observation:

This study reports on a patient with metastatic prostate cancer who experienced prostate-specific antigen (PSA) control.
The patient was treated with fulvestrant acetate, a selective estrogen receptor degrader.

Findings:

This represents the first published evidence of PSA control in metastatic prostate cancer using fulvestrant acetate.
Fulvestrant acetate demonstrated efficacy in managing PSA levels in this specific patient case.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Implications:

These findings suggest a potential therapeutic role for estrogen receptor (ER) signaling inhibitors like fulvestrant acetate in advanced prostate cancer.
Further research into ER-targeted therapies could offer new treatment avenues for patients with hormone-refractory metastatic prostate cancer.